SLAMF6 and Miyoshi myopathy: SLAMF6 is the target of SGN-352A, an ADC that is the focus of a recently initiated phase I trial for RRMM (NCT02954796), a study based in part on the observation that CD352 was found on 87% (13/15) of MM patient samples [53].